199 related articles for article (PubMed ID: 33045629)
1. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
4. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Heil J; Schaefgen B; Sinn P; Richter H; Harcos A; Gomez C; Stieber A; Hennigs A; Rauch G; Schuetz F; Sohn C; Schneeweiss A; Golatta M
Eur J Cancer; 2016 Dec; 69():142-150. PubMed ID: 27821317
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
8. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
10. Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy.
Amioka A; Masumoto N; Gouda N; Kajitani K; Shigematsu H; Emi A; Kadoya T; Okada M
Jpn J Clin Oncol; 2016 Apr; 46(4):303-9. PubMed ID: 26848078
[TBL] [Abstract][Full Text] [Related]
11. The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population.
Zhang Y; Shen J; Wu S; Zhou Y; Shao Z; Liu G
Surgery; 2020 Dec; 168(6):1115-1121. PubMed ID: 32917430
[TBL] [Abstract][Full Text] [Related]
12. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
13. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
[TBL] [Abstract][Full Text] [Related]
14. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer.
Marinovich ML; Houssami N; Macaskill P; von Minckwitz G; Blohmer JU; Irwig L
Int J Cancer; 2015 Jun; 136(11):2730-7. PubMed ID: 25387885
[TBL] [Abstract][Full Text] [Related]
16. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
17. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
19. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
20. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
Rauch GM; Kuerer HM; Adrada B; Santiago L; Moseley T; Candelaria RP; Arribas E; Sun J; Leung JWT; Krishnamurthy S; Yang WT
Ann Surg Oncol; 2018 Jul; 25(7):1953-1960. PubMed ID: 29667115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
